Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Technologies Reports Second-Quarter 2012 Results

Published: Wednesday, May 16, 2012
Last Updated: Wednesday, May 16, 2012
Bookmark and Share
Third-quarter fiscal year 2012 revenue guidance of $1.77 billion - $1.79 billion and non-GAAP earnings guidance of $0.82 - $0.84 per share.

Agilent Technologies Inc. has reported revenues of $1.73 billion for the second fiscal quarter ended April 30, 2012, 3 percent above one year ago.

Second-quarter GAAP net income was $255 million, or $0.72 per share. Last year's second-quarter GAAP net income was $200 million, or $0.56 per share.

During the second quarter, Agilent had intangible amortization of $26 million, transformational charges of $8 million, and acquisition and integration costs of $6 million.

The company also recognized a tax benefit of $11 million. Excluding these items and $9 million of other net benefits, Agilent reported second-quarter adjusted net income of $275 million, or $0.78 per share.

Bill Sullivan, Agilent president and CEO, said, "Our second-quarter performance demonstrated our ability to deliver strong results despite a challenging economic climate."

Electronic Measurement second-quarter revenues were up 5 percent over the prior year. Orders were up 13 percent from the same period last year. Growth was driven by wireless manufacturing.

Chemical Analysis revenues were 2 percent above one year ago. Orders were up 7 percent. Growth continued in key end markets, including petrochemical and food.

Life Sciences revenues grew 1 percent over last year, while orders declined 1 percent year over year. Solid performance in pharma was offset by weakness in academia and government.

Second-quarter ROIC was 26 percent. Agilent generated $353 million of cash from operations in the quarter.

Fiscal third-quarter 2012 revenues are expected to be in the range of $1.77 billion to $1.79 billion. Fiscal third-quarter non-GAAP earnings are expected to be in the range of $0.82 to $0.84 per share.

Agilent expects full fiscal-year 2012 revenue of $6.94 billion - $7.00 billion, and a tightened range of non-GAAP earnings of $3.18 - $3.24 per share.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent, PureHoney Partner to Develop New Applications for RapidFire/MS System
Companies to further develop the Agilent RapidFire/MS System, and independently create new workflows for pharma, biopharma, forensic toxicology, and metabolomics analysis.
Tuesday, November 01, 2016
Influential Cancer Researcher Receives Agilent Thought Leader Award
Biologist Scott Lowe receives award in recognition for his contributions to cancer biology.
Thursday, October 27, 2016
Agilent Collaborate with A*STAR’s Bioprocessing Technology Institute
Collaboration addresses a critical need in the biopharmaceutical industry.
Tuesday, July 14, 2015
Agilent Supports Inaugural Singapore-South Korea Symposium on Glycomics
Event follows collaboration to develop tools for analysis of biologics, vaccines.
Saturday, February 15, 2014
Agilent Reports Fourth-Quarter Results
Agilent Technologies reported orders up 4 percent over one year ago to $1.83 billion with revenues of $1.72 billion, down 3 percent compared with one year ago.
Monday, November 18, 2013
Agilent and Seoul National University Hospital Collaborate
The strategic collaboration will focus on the development and verification of various biomarkers for the development of drugs, including narcotics, immune-suppressants and biomarkers.
Friday, October 18, 2013
Agilent Technologies and SomaLogic Enter Agreement
The agreement will expand access to SomaLogic's unbiased protein biomarker discovery platform.
Tuesday, August 13, 2013
Agilent Technologies Announces Winner of Fifth Annual Early Career Professor Award
Assistant Professor at Northwestern Recognized for Cancer Diagnostics Research.
Friday, May 10, 2013
Agilent Technologies and Chungnam National University Announce Glycomics Research Initiatives
The collaboration hopes to develop biomarkers and new therapeutic antibodies to combat diseases such as cancer.
Tuesday, April 02, 2013
Agilent and Applied Proteomics Will Collaborate
Collaboration to maximize capabilities of highly multiplexed protein assays.
Friday, March 08, 2013
Agilent Collaborating with Florida International University
Collaboration to further advance the identification and characterization of designer drugs.
Tuesday, February 26, 2013
Agilent Technologies and Ameritox Form Collaboration
Agilent Technologies Inc. and AmeritoxSM announced that they have formed a research collaboration that could accelerate analysis in the field of medication monitoring.
Tuesday, February 12, 2013
Agilent Technologies Collaborates with Gachon University
World-leading research laboratory at Gachon will have access to the latest technologies from Agilent and a beta test site for new solutions.
Monday, July 23, 2012
Agilent and Integrated Diagnostics Enter Strategic Partnership
The partnership will develop protein-based assays for early disease detection.
Wednesday, January 11, 2012
Agilent Technologies and Chungnam National University Collaborate to Further Glycomics Research
The university aims to identify and develop biomarkers for diseases.
Friday, August 26, 2011
Scientific News
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Protein-Based “Cancer Signature” Uncovered
Researchers investigated the expression of ribosomal proteins in human tissues and discovered a cancer type specific signature which could be used to predict the progression of the disease.
Ribosome Recycling as a Drug Target
Researchers explain mechanism that recycles bacterial ribosomes stalled on messenger RNAs that lack termination codons.
Predicting Leukaemia Development in Cancer Patients
Biomarker may predict which formerly treated cancer patients will develop highly fatal form of leukemia.
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
'Lab on the Skin' for Sweat Analysis
Northwestern University researchers develop a low-cost wearable electronic device that collects and analyzes sweat for health monitoring.
Toxoplasma’s Balancing Act Explained
Parasite’s method of rewiring our immune response leads to novel tool for drug tests.
Cancer Signaling Pathway Illuminating Way To Therapy
Researchers refine a pro-growth signalling pathway, common to cancers, that can kill cancer cells while leaving healthy cells unharmed.
Breast Cancer Cells Starve for Cystine
Depriving triple negative breast cancer, a treatment-resistant form of breast cancer, of cystine results in cancer cell death.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!